



Final Programme

EBMT Autoimmune Diseases Working Party Educational Meeting

Including a joint symposium with the UK Scleroderma Group

29-30 November 2013, Sheffield, UK Organizers: D. Farge-Bancel, J. Snowden





Dear Colleagues,

This two day educational meeting will cover different topics related to HSCT and other cellular therapies for severe autoimmune diseases. The first day will be devoted to systemic sclerosis and organised jointly with the UK Scleroderma Group. The second day is devoted to neurological and gastroenterological diseases. Both days will also have elements of basic science relating to cellular therapy in autoimmune diseases.

Attendance from many different specialists and scientific colleagues is expected, and we hope this unique collaborative meeting will generate ongoing 'cross-fertilization' of ideas for the future development of our specialities.

Best Regards,

Dominique Farge-Bancel and John Snowden

Course Faculty

Dominique Farge-E
John Snowden
David Abraham
Mohammed Akil
Tobias Alexander
Attilio Bondanza
Maya Buch
Richard Burt
Gerry Coghlan
Thomas Daikeler
Chris Denton
Fiona Dignan
Rafella Greco
Chris Hawkey

Bancel Chris Hewitt
Bernd Hohenstein
Arianne Herrick
Majid Kazmi
David Kiely
Katarina LeBlanc
Alan Lobo
Maria Carolina Olivera
Montserrat Rovira
Riccardo Saccardi
Basil Sharrack
Pam Shaw
Peter Taylor

Aims of the Meeting

The participants of the educational event will gain knowledge of:

- 1. Standard and cellular therapeutic approaches to severe systemic sclerosis
- 2. Assessment of the severe systemic sclerosis patient
- 3. Systemic sclerosis and graft-versushost disease: similarities and differences
- 4. Cellular therapy for neurological diseases
- 5. Cellular therapy for inflammatory bowel disease
- 6. Mechanisms of action of HSCT and cellular therapy in autoimmune diseases
- 7. Future directions in cell therapy for autoimmune diseases

Programme

Day 1 - Friday 29th November

10.00 - 11.00	UK Scleroderma Group Business Meeting	
	Registration, arrivals and coffee for other participants	
11.00 -11.10	Welcome and introduction	C. Denton, D. Farge, J. Snowden
	ere systemic sclerosis: revised pathophysiology. ition and current standard immunosuppressive approaches.	Chairs: J.Snowden, M. Akil
11.10 - 11.30	New perspectives for the physiopathology of systemic sclerosis: lessons from graft-versus-host disease (GvHD)	C. Denton
11.30 - 11.50	The importance of cardiopulmonary evaluation in systemic sclerosis	G. Coghlan, D. Kiely
11.50 - 12.10	The ESOS study	A. Herrick
Session II: Hei	matopoletic stem cell transplantation for systemic sclerosis	Chairs: R. Saccardi, M. Buch
12.10 - 12.30	Northwestern University experience in systemic sclerosis	R. Burt
12.30 - 12.45	ASTIS trial	D. Farge, J. van Laar, A. Tyndall
12.45 - 13.05	Ribeirão de Preto - University of São Paulo experience	M.C. Olivera
13.05 - 14.20	Lunch	
Session III: Syst	temic sclerosis and graft versus host disease: I differences	Chairs: C. Denton, M. Rovira
14.20 - 14.35	Experimental models of systemic sclerosis: relevance to graft-versus-host disease (GvHD)	D. Abraham
14.35 - 14.55	The HSCT expert's perspective	F. Dignan
14.55 - 15.10	Skin histology after HSCT in systemic sclerosis	T. Daikeler
15.10 - 15.25	Biomarkers in graft-versus-host disease (GvHD)	A. Bondanza
15.30-16.00	Coffee Break	
Session IV: Fut	ure directions for severe systemic sclerosis	Chairs: R. Burt, C. Denton
16.00 - 16.20	Extracorporeal Photopheresis (ECP): from graft-versus-host disease to SSc	P. Taylor
16.20 - 16.40	Immune reconstitution after HSCT for autoimmune diseases: from current experience to standardization	T. Alexander
16.40 - 17.00	HSCT and/mesenchymal stem cells for the systemic sclerosis specialist	D. Farge
17.00 - 17.15	Quality and safety of HSCT in autoimmune diseases	J. Snowden
17.15 - 17.30	Discussion, close and thanks	D. Farge, C. Denton, J. Snowden

Programme

Day 2 - Saturday 30th November

08.30 - 10.00	ADWP Business meeting	D. Farge, J. Snowden,
a chaig La chays	Coffee Break	M. Badoglio
Session V: Ce	llular and immune therapies for neurological diseases	Chairs: K. Leßlanc, B. Sharrack
10.30 - 10.50	, was a series of that apple selectors	R. Saccardi
10.50 - 11.10	Motor neurone disease: is there a role for stem cell transplantation?	P. Shaw, C. Hewitt
11.10 - 11.25	Neuromyelitis optica (NMO)	R. Greco
11.25 - 11.40	Chronic inflammatory demyelinating polyneuropathy (CIDP)	M. Kazmi
11.40 - 12.10	Northwestern University experience in multiple sclerosis	R. Burt
12.10 - 12.30	Immunoabsorption as an alternative approach for the treatment of autoimmune diseases of the nervous system	B. Hohenstein
12.30 - 12.55	Panel Discussion	R. Saccardi, B. Sharrack
13.90 - 14.90		
Session VI: Infl	ammatory bowel disease	Chars: M. Kazmi, A. Lobo
14.00 - 14.15	Randomised clinical trials of HSCT: what can we learn from the ASTIC study?	C. Hawkey
14.15 - 14.30	Practical challenges in autologous HSCT for Crohn's disease: the haematologist's perspective	M. Rovira
Session VII: Fut autoimmune o	ture Directions in HSCT and cellular therapy in diseases	Chairs: C. Hawkey, D. Farge
14.30 - 14.55	The future of cellular therapy for immunomodulation: from graft-versus-host disease to autoimmune diseases	K. LeBlanc
14.55 - 15.15	Rebooting dysfunctional immune systems with HSCT: from bench to beside	T. Alexander, A. Bondanza
15.15 - 15.30	Discussion: Future grant applications for cell therapy in autoimmune diseases: the EBMT perspectives	K. LeBlanc, J.Snowden, D. Farge
16.00	Close	

Complementary Programme

Informal dinner - Friday 29th November

19.30 - 22.30 Traditional British dishes and real ale tasting at the Cricket Inn - coaches from course venue